Australia

/Australia

Early Hormone Therapy In Men With A Rising PSA Live Longer Then Men Who Delay Therapy – A Phase 3 Trial

The standard of care is to offer androgen deprivation therapy (ADT) to men with prostate cancer who have a rising prostate specific antigen (PSA) after an attempt to cure their cancer with primary therapy that has failed (PSA relapse) or in men who are considered not suitable for curative treatment. The question is what is the optimal timing to begin ADT. Researchers asked if immediate ADT improves overall survival compared with delayed therapy. They created a randomized, multi-center, phase 3, non-blinded trial; recruiting men from 29 oncology centers in Australia, New Zealand, and Canada. Eligibility included men with prostate cancer [...]

A New Model To Fight Prostate Cancer Coming In New Zealand & Australia

It has been announced that two important players in the fight against prostate cancer in New Zealand and Australia, ANZUP Cancer Trials Group (ANZUP) and the Prostate Cancer Foundation of Australia (PCFA) will work together to fund and implement new clinical trials. ANZUP, which is one of the leading collaborative trials group for urogenital and prostate cancer in Australia and New Zealand along with the PCFA joining together should hasten the development of additional clinical trials coming from that part of the world. Both organizations have a positive history of working together for many years. According to ANZUP CEO Margaret [...]

スーパーコピーブランド ロレックススーパーコピー オメガスーパーコピー ブルガリスーパーコピー ブライトリングスーパーコピー カルティエスーパーコピー シャネル時計コピー IWCスーパーコピー フランクミュラースーパーコピー パネライスーパーコピー タグホイヤースーパーコピー ウブロスーパーコピー ガガミラノスーパーコピー ルイヴィトンスーパーコピー シャネルスーパーコピー エルメススーパーコピー グッチスーパーコピー ボッテガヴェネタスーパーコピー プラダスーパーコピー セリーヌスーパーコピー ロレックススーパーコピー ウブロスーパーコピー